Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
939
mi
from 91732
Tacoma, WA
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
939
mi
from 91732
Tacoma, WA
Click here to add this to my saved trials
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
1745
mi
from 91732
Green Bay, WI
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1745
mi
from 91732
Green Bay, WI
Click here to add this to my saved trials
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
1654
mi
from 91732
Madison, WI
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1654
mi
from 91732
Madison, WI
Click here to add this to my saved trials
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
1722
mi
from 91732
Milwaukee, WI
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1722
mi
from 91732
Milwaukee, WI
Click here to add this to my saved trials
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
8190
mi
from 91732
Adelaide,
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
8190
mi
from 91732
Adelaide,
Click here to add this to my saved trials
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
2130
mi
from 91732
Saint Petersburg, FL
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2130
mi
from 91732
Saint Petersburg, FL
Click here to add this to my saved trials
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
1835
mi
from 91732
Muncie, IN
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1835
mi
from 91732
Muncie, IN
Click here to add this to my saved trials
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
1691
mi
from 91732
Bay Saint Louis, MS
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
1691
mi
from 91732
Bay Saint Louis, MS
Click here to add this to my saved trials
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
2371
mi
from 91732
Bala-Cynwyd, PA
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
2371
mi
from 91732
Bala-Cynwyd, PA
Click here to add this to my saved trials
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
2281
mi
from 91732
Washington,
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
2436
mi
from 91732
Bronx, NY
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2436
mi
from 91732
Bronx, NY
Click here to add this to my saved trials
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)
Status: Enrolling
Updated:  12/31/1969
356
mi
from 91732
Scottsdale, AZ
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
356
mi
from 91732
Scottsdale, AZ
Click here to add this to my saved trials
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)
Status: Enrolling
Updated:  12/31/1969
2141
mi
from 91732
Jacksonville, FL
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Florida
2141
mi
from 91732
Jacksonville, FL
Click here to add this to my saved trials
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)
Status: Enrolling
Updated:  12/31/1969
1524
mi
from 91732
Rochester, MN
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
Early Changes In Multiparametric MRI In Prostate Cancer
Early Changes in Multiparametric MRI in Response to Neoadjuvant Androgen Deprivation and External Beam Radiation Therapy for Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
2578
mi
from 91732
Boston, MA
Early Changes In Multiparametric MRI In Prostate Cancer
Early Changes in Multiparametric MRI in Response to Neoadjuvant Androgen Deprivation and External Beam Radiation Therapy for Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Early Changes In Multiparametric MRI In Prostate Cancer
Early Changes in Multiparametric MRI in Response to Neoadjuvant Androgen Deprivation and External Beam Radiation Therapy for Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
2578
mi
from 91732
Boston, MA
Early Changes In Multiparametric MRI In Prostate Cancer
Early Changes in Multiparametric MRI in Response to Neoadjuvant Androgen Deprivation and External Beam Radiation Therapy for Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Status: Enrolling
Updated:  12/31/1969
1785
mi
from 91732
Birmingham, AL
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Status: Enrolling
Updated: 12/31/1969
Birmingham VA Medical Center, Birmingham, AL
1785
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Status: Enrolling
Updated:  12/31/1969
1924
mi
from 91732
Decatur, GA
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Status: Enrolling
Updated: 12/31/1969
Atlanta VA Medical and Rehab Center, Decatur, GA
1924
mi
from 91732
Decatur, GA
Click here to add this to my saved trials
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Status: Enrolling
Updated:  12/31/1969
2373
mi
from 91732
Philadelphia, PA
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Status: Enrolling
Updated: 12/31/1969
Philadelphia VA Medical Center, Philadelphia, PA
2373
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer
F18 NaF PET/CT and Whole Body and Axial MRI for the Detection of Metastases in Patients With Biochemical Recurrence of Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
4
mi
from 91732
Duarte, CA
Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer
F18 NaF PET/CT and Whole Body and Axial MRI for the Detection of Metastases in Patients With Biochemical Recurrence of Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
City of Hope Medical Center
4
mi
from 91732
Duarte, CA
Click here to add this to my saved trials
Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer
F18 NaF PET/CT and Whole Body and Axial MRI for the Detection of Metastases in Patients With Biochemical Recurrence of Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
8
mi
from 91732
South Pasadena, CA
Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer
F18 NaF PET/CT and Whole Body and Axial MRI for the Detection of Metastases in Patients With Biochemical Recurrence of Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
City of Hope South Pasadena
8
mi
from 91732
South Pasadena, CA
Click here to add this to my saved trials
Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer
Phase 1 Study: A Prospective, Multi-center, Single Arm Study - Evaluation of the Safety and Feasibility of MRI-guided Transurethral Ultrasound Therapy for the Ablation of Prostate Tissue in Patients With Localized Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
1960
mi
from 91732
Royal Oak, MI
Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer
Phase 1 Study: A Prospective, Multi-center, Single Arm Study - Evaluation of the Safety and Feasibility of MRI-guided Transurethral Ultrasound Therapy for the Ablation of Prostate Tissue in Patients With Localized Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
William Beaumont Hospital
1960
mi
from 91732
Royal Oak, MI
Click here to add this to my saved trials
Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer
Phase 1 Study: A Prospective, Multi-center, Single Arm Study - Evaluation of the Safety and Feasibility of MRI-guided Transurethral Ultrasound Therapy for the Ablation of Prostate Tissue in Patients With Localized Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
2062
mi
from 91732
London,
Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer
Phase 1 Study: A Prospective, Multi-center, Single Arm Study - Evaluation of the Safety and Feasibility of MRI-guided Transurethral Ultrasound Therapy for the Ablation of Prostate Tissue in Patients With Localized Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
London Health Science Centre
2062
mi
from 91732
London,
Click here to add this to my saved trials
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated:  12/31/1969
2344
mi
from 91732
Anchorage, AK
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated: 12/31/1969
Site US00009
2344
mi
from 91732
Anchorage, AK
Click here to add this to my saved trials
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated:  12/31/1969
1966
mi
from 91732
Detroit, MI
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated: 12/31/1969
Site US00001
1966
mi
from 91732
Detroit, MI
Click here to add this to my saved trials
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated:  12/31/1969
2351
mi
from 91732
New York, NY
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated: 12/31/1969
Site US10047
2351
mi
from 91732
New York, NY
Click here to add this to my saved trials
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated:  12/31/1969
2319
mi
from 91732
Syracuse, NY
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated: 12/31/1969
Site US10046
2319
mi
from 91732
Syracuse, NY
Click here to add this to my saved trials
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated:  12/31/1969
2199
mi
from 91732
Durham, NC
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated: 12/31/1969
Site US10016
2199
mi
from 91732
Durham, NC
Click here to add this to my saved trials
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated:  12/31/1969
1223
mi
from 91732
Dallas, TX
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated: 12/31/1969
Site US10002
1223
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated:  12/31/1969
961
mi
from 91732
Seattle, WA
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated: 12/31/1969
Site: US10533
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated:  12/31/1969
6127
mi
from 91732
Berazategui,
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated: 12/31/1969
Site AR54001
6127
mi
from 91732
Berazategui,
Click here to add this to my saved trials
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated:  12/31/1969
2436
mi
from 91732
Bronx, NY
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Enrolling
Updated: 12/31/1969
Site US10026
2436
mi
from 91732
Bronx, NY
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
426
mi
from 91732
Tucson, AZ
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Urological Associates of Southern Arizona, PC
426
mi
from 91732
Tucson, AZ
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
817
mi
from 91732
Denver, CO
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Urology Center of Colorado
817
mi
from 91732
Denver, CO
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
2134
mi
from 91732
Tampa, FL
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer and Research Center
2134
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
1718
mi
from 91732
Melrose Park, IL
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Uro Partners/ RMD Clinical Research
1718
mi
from 91732
Melrose Park, IL
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
1852
mi
from 91732
Fort Wayne, IN
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Fort Wayne Medical Oncology and Hematology, Lutheran Hospital, Parkview Regional Medical Center
1852
mi
from 91732
Fort Wayne, IN
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
1300
mi
from 91732
Omaha, NE
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
GU Research Network, LLC
1300
mi
from 91732
Omaha, NE
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
2478
mi
from 91732
East Setauket, NY
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
North Shore Hematology Oncology Associates
2478
mi
from 91732
East Setauket, NY
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
2319
mi
from 91732
Syracuse, NY
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Associated Medical Professionals of New York PLLC
2319
mi
from 91732
Syracuse, NY
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
2217
mi
from 91732
Raleigh, NC
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Raleigh Hematology Oncology Associates D.B.A., Cancer Centers of North Carolina
2217
mi
from 91732
Raleigh, NC
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
2234
mi
from 91732
Myrtle Beach, SC
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Carolina Urologic Research Center
2234
mi
from 91732
Myrtle Beach, SC
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
1759
mi
from 91732
Nashville, TN
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Urology Associates
1759
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
2350
mi
from 91732
Virginia Beach, VA
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Urology of Virginia, PLLC
2350
mi
from 91732
Virginia Beach, VA
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
961
mi
from 91732
Seattle, WA
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Virginia Mason Medical Center, Virginia Mason Hospital
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
939
mi
from 91732
Tacoma, WA
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Northwest Medical Specialties, Rainier Physicians
939
mi
from 91732
Tacoma, WA
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
11
mi
from 91732
Los Angeles, CA
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
U.S.C./Norris Comprehensive Cancer Center
11
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
2486
mi
from 91732
New Haven, CT
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine
2486
mi
from 91732
New Haven, CT
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
2301
mi
from 91732
Baltimore, MD
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Medicine- The Sidney Kimmel Comprehensive Cancer Center
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
2033
mi
from 91732
Cleveland, OH
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
The Cleveland Clinic, Taussig Cancer Institute
2033
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials